MARKET

BDTX

BDTX

Black Diamond Therapeutics, Inc.
NASDAQ
2.710
+0.020
+0.74%
After Hours: 2.720 +0.01 +0.37% 19:59 12/04 EST
OPEN
2.700
PREV CLOSE
2.690
HIGH
2.720
LOW
2.475
VOLUME
2.50M
TURNOVER
--
52 WEEK HIGH
4.940
52 WEEK LOW
1.195
MARKET CAP
154.40M
P/E (TTM)
7.47
1D
5D
1M
3M
1Y
5Y
1D
This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 17h ago
Guggenheim Downgrades Black Diamond Therapeutic to Neutral
Benzinga · 17h ago
Black Diamond Therapeutics (BDTX) Gets a Buy from Piper Sandler
TipRanks · 19h ago
Black Diamond Therapeutics (BDTX): Valuation Check After New Phase 2 Silevertinib Data and Glioblastoma Trial Plans
Simply Wall St · 1d ago
Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
TipRanks · 1d ago
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data
Benzinga · 1d ago
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
TipRanks · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
More
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Webull offers Black Diamond Therapeutics Inc stock information, including NASDAQ: BDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDTX stock methods without spending real money on the virtual paper trading platform.